JP6345645B2 - 横隔膜機能を向上させるための方法 - Google Patents

横隔膜機能を向上させるための方法 Download PDF

Info

Publication number
JP6345645B2
JP6345645B2 JP2015503681A JP2015503681A JP6345645B2 JP 6345645 B2 JP6345645 B2 JP 6345645B2 JP 2015503681 A JP2015503681 A JP 2015503681A JP 2015503681 A JP2015503681 A JP 2015503681A JP 6345645 B2 JP6345645 B2 JP 6345645B2
Authority
JP
Japan
Prior art keywords
pyrazin
imidazo
alkyl
prop
enyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015503681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516957A5 (https=
JP2015516957A (ja
Inventor
ジェフリー アール． ジャスパー，
ジェフリー アール． ジャスパー，
ファディー マリック，
ファディー マリック，
ダレン ティー． フウィー，
ダレン ティー． フウィー，
Original Assignee
サイトキネティックス， インコーポレイテッド
サイトキネティックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイトキネティックス， インコーポレイテッド, サイトキネティックス， インコーポレイテッド filed Critical サイトキネティックス， インコーポレイテッド
Publication of JP2015516957A publication Critical patent/JP2015516957A/ja
Publication of JP2015516957A5 publication Critical patent/JP2015516957A5/ja
Application granted granted Critical
Publication of JP6345645B2 publication Critical patent/JP6345645B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015503681A 2012-04-02 2013-04-01 横隔膜機能を向上させるための方法 Expired - Fee Related JP6345645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619261P 2012-04-02 2012-04-02
US61/619,261 2012-04-02
PCT/US2013/034824 WO2013151938A1 (en) 2012-04-02 2013-04-01 Methods for improving diaphragm function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018098858A Division JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法

Publications (3)

Publication Number Publication Date
JP2015516957A JP2015516957A (ja) 2015-06-18
JP2015516957A5 JP2015516957A5 (https=) 2016-06-02
JP6345645B2 true JP6345645B2 (ja) 2018-06-20

Family

ID=49300969

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015503681A Expired - Fee Related JP6345645B2 (ja) 2012-04-02 2013-04-01 横隔膜機能を向上させるための方法
JP2018098858A Ceased JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法
JP2020104620A Pending JP2020147607A (ja) 2012-04-02 2020-06-17 横隔膜機能を向上させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018098858A Ceased JP2018131460A (ja) 2012-04-02 2018-05-23 横隔膜機能を向上させるための方法
JP2020104620A Pending JP2020147607A (ja) 2012-04-02 2020-06-17 横隔膜機能を向上させるための方法

Country Status (15)

Country Link
US (2) US20150065525A1 (https=)
EP (1) EP2834269A4 (https=)
JP (3) JP6345645B2 (https=)
KR (1) KR20160046693A (https=)
CN (2) CN104379597A (https=)
AU (2) AU2013243671B2 (https=)
BR (1) BR112014024552A2 (https=)
CA (1) CA2868507A1 (https=)
EA (1) EA031183B1 (https=)
HK (1) HK1206364A1 (https=)
IL (2) IL234885A0 (https=)
MX (1) MX354965B (https=)
PH (1) PH12014502217A1 (https=)
SG (2) SG10201701101YA (https=)
WO (1) WO2013151938A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
CA2869675C (en) * 2012-04-11 2022-06-14 Cytokinetics, Inc. Methods for improving resistance to skeletal muscle fatigue
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
US10308615B2 (en) 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
JP7728184B2 (ja) 2019-06-19 2025-08-22 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
JP7687968B2 (ja) 2019-06-19 2025-06-03 エフ． ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
WO2020254343A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
AU2020311940A1 (en) 2019-07-11 2022-02-03 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20240382564A1 (en) * 2023-04-17 2024-11-21 Allysta Pharmaceuticals, Inc. Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) * 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
US7201898B2 (en) * 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CN1283793C (zh) * 2002-06-03 2006-11-08 北京大学 具有骨骼肌刺激活性和免疫调节作用的趋化素样因子超家族
US20050049241A1 (en) * 2003-08-08 2005-03-03 Carruthers Nicholas I. Pyridyl piperazinyl ureas
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
PL2069352T3 (pl) * 2006-08-02 2014-03-31 Cytokinetics Inc Określone cząstki chemiczne, kompozycje i sposoby
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US8088793B2 (en) * 2007-08-15 2012-01-03 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
NL2001694C2 (en) * 2008-06-18 2009-12-22 Nasophlex B V Ear stimulator for producing a stimulation signal to an ear.
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos

Also Published As

Publication number Publication date
HK1206364A1 (en) 2016-01-08
AU2017272286A1 (en) 2018-01-04
IL234885A0 (en) 2014-12-31
AU2013243671B2 (en) 2017-09-21
US20150065525A1 (en) 2015-03-05
EP2834269A4 (en) 2015-12-30
MX354965B (es) 2018-03-27
CN108553467A (zh) 2018-09-21
JP2018131460A (ja) 2018-08-23
IL267876A (en) 2019-09-26
AU2017272286B2 (en) 2019-05-09
CN104379597A (zh) 2015-02-25
AU2013243671A1 (en) 2014-10-16
BR112014024552A2 (pt) 2017-09-19
JP2020147607A (ja) 2020-09-17
WO2013151938A1 (en) 2013-10-10
CA2868507A1 (en) 2013-10-10
PH12014502217A1 (en) 2015-01-12
EP2834269A1 (en) 2015-02-11
KR20160046693A (ko) 2016-04-29
EA201491605A1 (ru) 2015-03-31
EA031183B1 (ru) 2018-11-30
IL267876B (en) 2021-03-25
SG11201406270YA (en) 2014-10-30
SG10201701101YA (en) 2017-04-27
US20170266192A1 (en) 2017-09-21
MX2014011881A (es) 2016-07-20
JP2015516957A (ja) 2015-06-18

Similar Documents

Publication Publication Date Title
JP6345645B2 (ja) 横隔膜機能を向上させるための方法
CN105859712B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
JP6609631B2 (ja) 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
JP6535727B2 (ja) 骨格筋疲労に対する耐性を向上させるための方法
JP2022506687A (ja) ピリダジノン化合物およびその使用
WO2014095774A1 (de) Bet-proteininhibitorische dihydropyridopyrazinone
JP2014505091A (ja) ６−シクロブチル−１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用
CN107108671A (zh) 作为raf激酶抑制剂的化合物和组合物
TW201831486A (zh) Ｐｄｅ２抑制劑
TW201321353A (zh) 胺基甲酸酯／尿素衍生物
CN115843295B (zh) Nampt调节剂
EP3672957A1 (en) Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
JP7787893B2 (ja) Ｎａｍｐｔモジュレーターとして有用なピラゾール誘導体
HK1261324A1 (en) Methods for improving diaphragm function
WO2025148955A1 (zh) 含有嘌呤环的化合物及其用途
WO2024131265A1 (zh) 用于治疗PI3Kγ介导的疾病的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160401

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180523

R150 Certificate of patent or registration of utility model

Ref document number: 6345645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees